GW Pharma shares surge on positive PhIII followup; Illumina leads $18M round for Stilla's DNA tech
→ GW Pharma $GWPH already won their big FDA approval to sell Epidiolex for rare seizure cases, setting the groundbreaking cannabinoid drug on track to …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.